Figure 7.

Therapeutic efficacy of TSL-Dox with and without closed-loop FUS hyperthermia. (A) Analysis of the GL261 cell viability (in vitro) between TSL-Dox with and without hyperthermia (10 min at 41.5 °C). (B) Estimation of tumor growth based on T₂ weighted MRI images taken on the treatment day. (C) Representative MRI images of control and FUS groups (2 mice from each group) with outlines (black circle) showing the tumor growth (treatment day - top vs. post 7 days - bottom). (D) Thermometry image fused over a T₂ weighted MR image. (E) Temperature profiles of bi-state closed-loop controller (low/high) from hyperthermia experiments demonstrating that the MRgFUS treated mice reached the desired threshold for the duration of applied thermal stress (~10 min). (F) Survival analysis in GL261 tumor mice (TSL-Dox with and without hyperthermia at 41.5 °C for 10 min) (P = 0.032). The increase in overall survival in the TSL-Dox with hyperthermia was 15.6 ± 4.0 days (median = 16) and in the TSL-Dox alone was 10.7 ± 3.4 days (median = 9) from the day the treatment started. The number of mice used per group was 7.